Scholar Rock Holding Corporation (SRRK)

USD 41.25

(-5.5%)

Market Cap (In USD)

3.86 Billion

Revenue (In USD)

-

Net Income (In USD)

-165.78 Million

Avg. Volume

768.09 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
6.76-46.185
PE
-
EPS
-
Beta Value
0.478
ISIN
US80706P1030
CUSIP
80706P103
CIK
1727196
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Jay Thomas Backstrom M.D., M.P.H.
Employee Count
-
Website
https://scholarrock.com
Ipo Date
2018-05-25
Details
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.